Summary:
- The article critically examines the emerging clinical data regarding the use of GLP-1 receptor agonists, typically prescribed for diabetes and obesity, as potential treatments for major depressive disorder.
- It highlights a discrepancy between initial observational optimism and more rigorous, nuanced clinical trial results, emphasizing the complexity of neurobiological pathways involved in metabolic and psychiatric health.